ARGX-117, a therapeutic complement inhibiting antibody targeting C2.

Authors:
Van de Walle I; Silence K; Budding K; Van de Ven L; Dijkxhoorn K and 17 more

Journal:
J Allergy Clin Immunol

Publication Year: 2020

DOI:
10.1016/j.jaci.2020.08.028

PMCID:
PMC7485568

PMID:
32926878

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Allergy Clin Immunol

Abbreviation: J Allergy Clin Immunol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Autoimmunity and immunodeficiency associated with monoallelic LIG4 mutations via haploinsufficiency.
Jauch AJ; Bignucolo O; Seki S and 34 more (2023) - Transparency Score: 3/6
Development of mouse models with restricted HLA-B∗57:01 presentation for the study of flucloxacilli…
Ananthula S; Krishnaveni Sivakumar K; Cardone M and 6 more (2023) - Transparency Score: 3/6
Eosinophils promote effector functions of lung group 2 innate lymphoid cells in allergic airway inf…
LeSuer WE; Kienzl M; Ochkur SI and 7 more (2023) - Transparency Score: 4/6
Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and m…
Bucciol G; COVID Human Genetic Effort; Meyts I. (2023) - Transparency Score: 3/6
Phospholipid remodeling and its derivatives are associated with COVID-19 severity.
Wei J; Liu X; Xiao W and 13 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure of conflicts of interest: I. Van de Walle, L. Van de Ven, S. Gabriels, J.-M. Percier, C. Blanchetot, and H. de Haard are employees of and have equity ownership in argenx. K. Silence and C. E. Hack are consultants for argenx. P. J. Simons, L. Cox, and L. Boon are employees of Bioceros BV. P. Boross and C. E. Hack are employees of Prothix BV. R. Holgate is an employee of Antitope/Abzena Ltd. The rest of the authors declare that they have no relevant conflicts of interest."

Evidence found in paper:

"This work was supported by an LSH Impuls Programme grant from The Life Science and Health—Topconsortium for Knowledge and Innovation and project 40-43100-98-013 from the 10.13039/501100002997Dutch Kidney Foundation."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025